137 related articles for article (PubMed ID: 26867486)
1. 4H-Chromene-based anticancer agents towards multi-drug resistant HL60/MX2 human leukemia: SAR at the 4th and 6th positions.
Puppala M; Zhao X; Casemore D; Zhou B; Aridoss G; Narayanapillai S; Xing C
Bioorg Med Chem; 2016 Mar; 24(6):1292-7. PubMed ID: 26867486
[TBL] [Abstract][Full Text] [Related]
2. Ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017): a novel scaffold that resensitizes multidrug resistant leukemia cells to chemotherapy.
Das SG; Hermanson DL; Bleeker N; Lowman X; Li Y; Kelekar A; Xing C
ACS Chem Biol; 2013 Feb; 8(2):327-35. PubMed ID: 23102022
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
Aridoss G; Zhou B; Hermanson DL; Bleeker NP; Xing C
J Med Chem; 2012 Jun; 55(11):5566-81. PubMed ID: 22582991
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationship and molecular mechanisms of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and its analogues.
Das SG; Srinivasan B; Hermanson DL; Bleeker NP; Doshi JM; Tang R; Beck WT; Xing C
J Med Chem; 2011 Aug; 54(16):5937-48. PubMed ID: 21780800
[TBL] [Abstract][Full Text] [Related]
5. Antiproliferative effect, cell cycle arrest and apoptosis generation of novel synthesized anticancer heterocyclic derivatives based 4H-benzo[h]chromene.
Alblewi FF; Okasha RM; Hritani ZM; Mohamed HM; El-Nassag MAA; Halawa AH; Mora A; Fouda AM; Assiri MA; Al-Dies AM; Afifi TH; El-Agrody AM
Bioorg Chem; 2019 Jun; 87():560-571. PubMed ID: 30928878
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Anticancer Study of Novel 4H-Chromen Derivatives.
Lu X; Dong G; Zheng Y; Zhang C; Qiu Y; Lua T; Zhou X
Anticancer Agents Med Chem; 2017; 17(8):1070-1083. PubMed ID: 27141877
[TBL] [Abstract][Full Text] [Related]
7. Exploring the Structure-Activity Relationship and Mechanism of a Chromene Scaffold (CXL Series) for Its Selective Antiproliferative Activity toward Multidrug-Resistant Cancer Cells.
Bian T; Chandagirikoppal Vijendra K; Wang Y; Meacham A; Hati S; Cogle CR; Sun H; Xing C
J Med Chem; 2018 Aug; 61(15):6892-6903. PubMed ID: 29995404
[TBL] [Abstract][Full Text] [Related]
8. A novel SERCA inhibitor demonstrates synergy with classic SERCA inhibitors and targets multidrug-resistant AML.
Bleeker NP; Cornea RL; Thomas DD; Xing C
Mol Pharm; 2013 Nov; 10(11):4358-66. PubMed ID: 24079514
[TBL] [Abstract][Full Text] [Related]
9. Development of potential anticancer agents and apoptotic inducers based on 4-aryl-4H chromene scaffold: Design, synthesis, biological evaluation and insight on their proliferation inhibition mechanism.
Elshemy HAH; Zaki MA; Mahmoud AM; Khan SI; Chittiboyina AG; Kamal AM
Bioorg Chem; 2022 Jan; 118():105475. PubMed ID: 34800886
[TBL] [Abstract][Full Text] [Related]
10. Design of New Benzo[h]chromene Derivatives: Antitumor Activities and Structure-Activity Relationships of the 2,3-Positions and Fused Rings at the 2,3-Positions.
Okasha RM; Alblewi FF; Afifi TH; Naqvi A; Fouda AM; Al-Dies AM; El-Agrody AM
Molecules; 2017 Mar; 22(3):. PubMed ID: 28335470
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analogues.
Das SG; Doshi JM; Tian D; Addo SN; Srinivasan B; Hermanson DL; Xing C
J Med Chem; 2009 Oct; 52(19):5937-49. PubMed ID: 19743858
[TBL] [Abstract][Full Text] [Related]
12. 4-Aryl-4H-chromene-3-carbonitrile derivatives: evaluation of Src kinase inhibitory and anticancer activities.
Fallah-Tafti A; Tiwari R; Shirazi AN; Akbarzadeh T; Mandal D; Shafiee A; Parang K; Foroumadi A
Med Chem; 2011 Sep; 7(5):466-72. PubMed ID: 21801146
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of novel chromene derivatives of expected antitumor activity.
Kandeel MM; Kamal AM; Abdelall EK; Elshemy HA
Eur J Med Chem; 2013 Jan; 59():183-93. PubMed ID: 23220647
[TBL] [Abstract][Full Text] [Related]
14. CXL146, a Novel 4
Bian T; Tagmount A; Vulpe C; Vijendra KC; Xing C
Mol Pharmacol; 2020 Jun; 97(6):402-408. PubMed ID: 32276963
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, estrogen receptor binding affinity and molecular docking of pyrimidine-piperazine-chromene and -quinoline conjugates.
Parveen I; Ahmed N; Idrees D; Khan P; Hassan MI
Bioorg Med Chem Lett; 2017 Sep; 27(18):4493-4499. PubMed ID: 28797797
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of 4H-chromene, coumarin, 12H-chromeno[2,3-d]pyrimidine derivatives and some of their antimicrobial and cytotoxicity activities.
Sabry NM; Mohamed HM; Khattab ES; Motlaq SS; El-Agrody AM
Eur J Med Chem; 2011 Feb; 46(2):765-72. PubMed ID: 21216502
[TBL] [Abstract][Full Text] [Related]
17. Anti-proliferative and apoptotic effects of the derivatives from 4-aryl-4H-chromene family on human leukemia K562 cells.
Aryapour H; Mahdavi M; Mohebbi SR; Zali MR; Foroumadi A
Arch Pharm Res; 2012 Sep; 35(9):1573-82. PubMed ID: 23054714
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of antitumor activity of 9-methoxy-1H-benzo[f]chromene derivatives.
Elgaafary M; Lehner J; Fouda AM; Hamed A; Ulrich J; Simmet T; Syrovets T; El-Agrody AM
Bioorg Chem; 2021 Nov; 116():105402. PubMed ID: 34670333
[TBL] [Abstract][Full Text] [Related]
19. Exploitation of new chalcones and 4H-chromenes as agents for cancer treatment.
Pontes O; Costa M; Santos F; Sampaio-Marques B; Dias T; Ludovico P; Baltazar F; Proença F
Eur J Med Chem; 2018 Sep; 157():101-114. PubMed ID: 30081238
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of Mcl-1 confers multidrug resistance, whereas topoisomerase IIβ downregulation introduces mitoxantrone-specific drug resistance in acute myeloid leukemia.
Hermanson DL; Das SG; Li Y; Xing C
Mol Pharmacol; 2013 Aug; 84(2):236-43. PubMed ID: 23696245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
